Biogen Reports observational study Data for Ofatumumab in Atrial fibrillation

Biogen today announced observational study results for Ofatumumab in patients with Atrial fibrillation. The study demonstrated that Ofatumumab improves quality of life measures compared to standard of care or placebo. These results provide important insights into the treatment of Atrial fibrillation and support the continued development of Ofatumumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Ofatumumab was consistent with previous observations, with no new safety signals identified.